Quantification of rosiglitazone in rat plasma and tissues via LC-MS/MS: Method development, validation, and application in pharmacokinetic and tissue distribution studies

A bioanalytical method for the quantification of rosiglitazone in rat plasma and tissues (adipose tissue, heart, brain, bone, and kidney) using LC-MS/MS was developed and validated. Chromatographic separation was achieved on a Gemini C-18 column (50 x 4.6 mm, 3 mu m) using a mobile phase consisting of 10 mM ammonium formate (pH 4.0) and acetonitrile (10:90, v/v) at a flow rate of 0.8 mL/min and injection volume of 10 mu L (internal standard: pioglitazone). LC-MS detection was performed with multiple reaction monitoring mode using target ions at m/z -> 358.0 and m/z -> 357.67 for rosiglitazone and pioglitazone (internal standard), respectively. The calibration curve showed a good correlation coefficient (r(2)) over the concentration range of 1-10,000 ng/mL. The mean percentage recoveries of rosiglitazone were found to be over the range of 92.54-96.64%, with detection and lower quantification limit of 0.6 and 1.0 ng/mL, respectively. The developed method was validated per U.S. Food and Drug Administration guidelines and successfully utilized to measure rosiglitazone in plasma and tissue samples. Further, the developed method can be utilized for validating specific organ-targeting delivery systems of rosiglitazone in addition to conventional dosage forms.

Automated summary

This article describes a validated bioanalytical method for quantifying rosiglitazone in rat plasma and tissues using LC-MS/MS. The method showed good accuracy and sensitivity, with a good correlation coefficient in the calibration curve. The developed method can be used for measuring rosiglitazone in plasma and tissue samples, and may also be applicable for validating specific organ-targeting delivery systems of rosiglitazone.